Pregabalin, a nerve pain medication, now faces stricter controls. The Union health ministry has moved it to Schedule H1. This change aims t...

The report highlights the significant economic burden of tobacco use, particularly among low-income households, and underscores how reducin...

The proposed platform will enable real-time, end-to-end digital tracking of all regulated pharmaceutical products, covering every stage fro...

The Indian government is shaking up the pharmaceutical sector by slashing the review period for manufacturing applications for new drugs to...

India is developing a framework for over-the-counter (OTC) drugs, potentially allowing some prescription medications to be sold in general ...

Earlier, in January India's Drug Technical Advisory Board (DTAB), India's apex drug advisory body, deliberated on the issue of same brand n...

The Bill seeks to regulate the import, manufacture, distribution and sale of drugs, medical devices and cosmetics. It also seeks to ensure ...

In the representation, it was mentioned that Ketoprofen and Aceclofenac in cattle as toxic as Diclofenac and can kill vultures. Study showe...

The Centre is planning to introduce stringent guidelines on distribution practices for drug companies.

The FDC were banned by the Centre on the grounds that they involved "risk" to humans and safer alternatives were available.

A bench said that the 349 FDCs were banned pursuant to the Kokate Committee report, by notifications of the central government under Sectio...

Pharmaceutical companies have long used India as a dumping ground for irrational fixed dose combination (FDC) drugs rejected by other count...

New drugs that are already marketed in developed countries may be exempted from local clinical trials in India if subject experts vet their...

Habit-forming anti-biotics, anti -TB and other such drugs like diazepam sleeping pills will not be freely available at chemists from March ...

In the wake of opposition from industry and medical fraternity to the ban on anti-diabetes drug Pioglitazone, DTAB will review the decision...

The drug technical advisory board (DTAB) had put the drug under review due to complaints of side effects and approval without mandatory stu...

Industry and regulatory experts say the ban has come too late and in case of nimesulide, the prohibition will be ineffective.